Justia U.S. 9th Circuit Court of Appeals Opinion Summaries

Plaintiff filed suit against Novartis, manufacturer of Zometa, alleging products liability, negligent manufacture, negligent failure to warn, breach of express and implied warranty, and loss of consortium. On appeal, plaintiff contended that the district court erred by excluding the causation testimony offered by her expert when it found the testimony to be irrelevant and unreliable. The court concluded that the expert's testimony was relevant because it indicated that plaintiff's bisphosphonate use was a substantial factor in her development of bisphosphonate-related osteonecrosis of the jaw. The court also concluded that the expert's testimony was reliable where he used a differential diagnosis grounded in significant clinical experience and examination of medical records and literature. Accordingly, the court concluded that the expert's testimony created a genuine issue of material fact regarding the specific causal link between plaintiff's bisphosphonates treatment and her development of osteonecrosis of the jaw. The court reversed the district court's summary judgment in favor of Novartis and remanded. View "Messick v. Novartis Pharmaceuticals Corp." on Justia Law

Plaintiff filed a class action suit against Vital for its distribution of ZERO IMPACT protein bars that were erroneously marketed and labeled as having little to no impact on blood sugar. On appeal, Vital challenged the district court's sua sponte order remanding the suit to state court for failure to establish the amount in controversy requirement under the Class Action Fairness Act (CAFA), 28 U.S.C. 1453(c)(1). The court reversed and remanded, concluding that the undisputed Cimino declarations were sufficient to establish that CAFA's $5 million amount in controversy requirement was met. View "Watkins v. Vital Pharmaceuticals" on Justia Law

After an airplane was damaged in a runway accident, USAU indemnified the owner of the aircraft and brought a subrogation claim against Nabtesco. USAU alleged that the accident resulted from a defective component part, an actuator, manufactured by Nabtesco. The court affirmed the district court's order and held that the eighteen-year statute of repose set forth in the General Aviation Revitalization Act of 1994, 49 U.S.C. 40101, began to run from the date that the component part, along with the aircraft in which it was installed originally, was delivered to its first purchaser. View "United States Aviation Underwriters, Inc. v. Nabtesco Corp., et al" on Justia Law